Purpose Ameloblastoma (AM), a frequently encountered odontogenic epithelial neoplasm, demonstrates complex molecular pathogenesis involving dysregulation of cellular signaling networks. This study investigated the clinicopathological significance of Notch1 signaling pathway activation and its downstream effector CyclinD1 in jaw ameloblastoma progression. Methods Immunohistochemical profiling was conducted on 66 archived AM specimens and 23 normal oral mucosa (NOM) controls. Protein localization patterns and expression intensities were systematically analyzed using chi-square tests, Fisher’s exact test, and Spearman’s rank correlation (significance threshold α = 0.05). Results A notable proportion of jaw AM samples exhibited marked immunoreactivity for Notch1 and CyclinD1 proteins, predominantly localized in the cellular membrane and cytoplasm. Significantly elevated levels of Notch1 and CyclinD1 proteins were evident in AM compared to NOM (P < 0.05). The protein expression levels showed no association with AM subtype (P > 0.05), while a positive correlation between Notch1 and CyclinD1 expression was noted in AM (r = 0.509, P < 0.05). Conclusions The coordinated overexpression of Notch1-CyclinD1 axis in ameloblastoma pathogenesis suggests their synergistic involvement in tumor proliferation dynamics. These findings position the Notch signaling pathway as a potential therapeutic target for AM management strategies.

Genitourinary infections (GUIs) during pregnancy are a significant clinical concern linked to maternal morbidity. While Streptococcus is a common gut commensal and a known urogenital pathobiont, whether gut-resident Streptococcus plays a causal role in the etiology of pregnancy-related infections remains unclear due to confounding in observational studies. To investigate the potential causal effect of gut Streptococcus abundance on the risk of maternal genitourinary infection during pregnancy using Mendelian randomization (MR). We performed a two-sample MR analysis using publicly available genome-wide association study (GWAS) summary statistics. Genetic instruments for gut Streptococcus abundance were obtained from the MiBioGen consortium (N=18,340). Outcome data for maternal genitourinary infection (ICD-10 O23.x) were sourced from the FinnGen consortium (N=111,731). The inverse-variance weighted (IVW) method was used as the primary analysis, supplemented by sensitivity analyses (MR-Egger, weighted median, MR-PRESSO). We further assessed potential mediation via systemic inflammation (C-reactive protein, interleukin-6) and associations with eleven major adverse pregnancy outcomes (APOs). Genetically predicted higher gut Streptococcus abundance was associated with a reduced risk of maternal genitourinary infection (IVW odds ratio [OR] = 0.63, 95% confidence interval [CI]: 0.43–0.93, p = 0.020). Sensitivity analyses supported this protective association, with no evidence of horizontal pleiotropy (MR-Egger intercept p = 0.942) or significant heterogeneity. No causal effects were observed on systemic inflammatory markers (CRP, IL-6, all p > 0.05) or on major APOs, including postpartum haemorrhage, placental abruption, etc. This MR study provides genetic evidence supporting a causal, protective role of gut Streptococcus against the risk of clinically diagnosed genitourinary infection during pregnancy. This effect appears specific and is not mediated through the systemic inflammatory pathways examined, suggesting a localized mechanism within the genitourinary tract.